Ocular Therapeutix Inc. (NASDAQ:OCUL) reached a new 52-week low on Tuesday . The stock traded as low as $4.11 and last traded at $4.13, with a volume of 152,446 shares. The stock had previously closed at $4.38.

Several equities research analysts have weighed in on OCUL shares. BTIG Research restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, July 26th. Cowen and Company reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Monday, June 6th. Morgan Stanley reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Saturday, April 9th. Zacks Investment Research downgraded shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $48.00 price target on shares of Ocular Therapeutix in a report on Sunday, April 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Ocular Therapeutix presently has a consensus rating of “Buy” and an average target price of $27.45.

The firm’s 50 day moving average price is $5.16 and its 200-day moving average price is $8.28. The company’s market capitalization is $103.77 million.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.01. The company had revenue of $458 million for the quarter. Analysts anticipate that Ocular Therapeutix Inc. will post ($1.86) EPS for the current fiscal year.

In other Ocular Therapeutix news, CEO Amarpreet Sawhney acquired 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, June 9th. The stock was acquired at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the purchase, the chief executive officer now owns 573,733 shares of the company’s stock, valued at $3,844,011.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.